Therefore, NCCN guidelines v1.2022 state that cabazitaxel plus carboplatin should be considered for prostate cancer patients with unfavorable genomics defined by defects in at least 2 of TP53, Rb1, and PTEN. The gene discussed is PTEN; the disease is prostate cancer.